Project: AMR Rapid Diagnostic Tests

Acronym	AMR-RDT (Reference Number: JPIAMR_2016_N008)
Duration	01/01/2017 - 31/12/2017
Project Topic	Antimicrobial Resistance (AMR) has become a global threat and rapid diagnostics are urgently needed to tackle this challenge. To identify barriers to the development, implementation and use of rapid diagnostics and propose a roadmap to future solutions we are launching AMR Rapid Diagnostic Tests (AMR-RDT) as a multi-sectoral, multi-stakeholder and interdisciplinary working group with global reach. It brings together over 50 key individuals and organisations from 15 countries worldwide that are active in the field of diagnostics and antimicrobial resistance. This unprecedented body of expertise and the access it brings to national and international institutions, and networks will amplify the reach and implementation of the working group’s outputs. AMR-RDT will concentrate on five overarching topics: Need & Target Product Profiles, Technologies, Development Roadmaps, Business Models, and Behavioural Change. The working group will focus on human healthcare but also recognises the importance of One Health aspects. AMR-RDT is funded as a one-year project by the UK Medical Research Council under the frame of the Joint Planning Initiative on AMR (JPIAMR) and is coordinated by Till Bachmann at the University of Edinburgh.
Website	visit project website
Network	JPI AMR
Call	4th Joint Call: Research Networking Programmes

Project partner

Number	Name	Role	Country
1	University of Edinburgh	Coordinator	United Kingdom
2	North Bristol NHS Trust	Observer	United Kingdom
3	BioMérieux	Observer	France
4	KTH Royal Institute of Technology	Observer	Sweden
5	Omega Diagnostics	Observer	United Kingdom
6	NIHR Diagnostic Evidence Cooperative	Observer	United Kingdom
7	HemoCue	Observer	Sweden
8	British In Vitro Diagnostics Association	Observer	United Kingdom
9	Foundation for Innovative New Diagnostics	Observer	Switzerland
10	National Institute of Clinical and Health Excellence	Observer	United Kingdom
11	Osaka University	Observer	Japan
12	World Health Organization (WHO)	Observer	Switzerland
13	European Diagnostics Cluster Alliance	Observer	France
14	R-Biopharm	Observer	Germany
15	Fraunhofer Institute for Cell Therapy and Immunology	Observer	Germany
16	Curetis GmbH	Observer	Germany
17	Robert Koch Institute	Observer	Germany
18	University of Tromsø	Observer	Norway
19	Lahey Hospital & Medical Center and Harvard Medical School	Observer	United States
20	Antwerp University	Observer	Belgium
21	Ben-Gurion University	Observer	Israel
22	Chipcare	Observer	Canada
23	Ahimsa Fund	Observer	France
24	Erasmus MC University Medical Center	Observer	Netherlands
25	F2G	Observer	United States
26	University of Barcelona	Observer	Spain
27	University Hospital Münster	Observer	Germany
28	NHS Lothian	Observer	United Kingdom
29	Hyrax Biosciences	Observer	South Africa
30	Hahn-Schickard, University of Freiburg	Observer	Germany
31	Global Antibiotic R&D Partnership	Observer	Switzerland
32	University of Edinburgh	Observer	United Kingdom
33	Spectromics	Observer	United Kingdom
34	Public Health England	Observer	United Kingdom
35	Maastricht University	Observer	Netherlands
36	Charité University Medicine	Observer	Germany
37	University of Manitoba	Observer	Canada
38	Center for Disease Dynamics, Economics & Policy	Observer	India
39	London School of Hygiene & Tropical Medicine	Observer	United Kingdom
40	University of Edinburgh	Observer	United Kingdom
41	Max von Pettenkofer Institute Munich	Observer	Germany
42	University of Geneva	Observer	Switzerland
43	NHS England	Observer	United Kingdom
44	University of Adelaide	Observer	Australia
45	Centre for Cellular and Molecular Platforms	Observer	India
46	University of Frankfurt	Observer	Germany
47	Farr Institute Health Informatics Research	Observer	United Kingdom
48	University of Bologna	Observer	Italy
49	KTH Royal Institute of Technology	Observer	Sweden
50	HHL Leipzig Graduate School of Management	Observer	Germany